20 Most Profitable Stocks of the Last 20 Years

Page 11 of 18

8. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Net Income (TTM): $4.58 billion

Operating Margin: 26.72%

Market Capitalization: $77.31 billion

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable stocks.

TheFly reported on January 22 that Evercore ISI increased its price target for REGN to $875 from $750 and maintained an Outperform rating on the stock. The firm expressed confidence in REGN’s updated outlook and recent pricing actions. Evercore ISI identified Dupixent and Eylea HD as key players in the company’s growth and noted that both products are well-positioned to sustain current competitiveness and improve future performance.

Similarly, earlier this month, on January 8, Goldman Sachs also raised its price target for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $914 from $807 and gave it a Buy rating. The firm cited strong sector performance in 2025 and expects the positive momentum to continue into 2026, which is supported by favorable market conditions, easing policy risks, and potential M&A activity.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company specializing in the discovery, development, and commercialization of innovative medicines for serious diseases.

Page 11 of 18